Flecainide acetate for the treatment of atrial and ventricular arrhythmias

Author： Apostolakis Stavros   Oeff Michael   Tebbe Ulrich   Fabritz Larissa   Breithardt Günter   Kirchhof Paulus  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.3, 2013-02, pp. : 347-357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure

By  

Current Pharmaceutical Design, Vol. 21, Iss. 8, 2015-03 ,pp. : 1011-1029

Bentham Science Publishers

Access to resources Recommend Favorite

Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias

By Barrett T.D.   Hayes E.S.   Walker M.J.A.  

European Journal of Pharmacology, Vol. 285, Iss. 3, 1995-10 ,pp. : 229-238

Elsevier

Access to resources Recommend Favorite

Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

By Brendel Joachim   Peukert Stefan  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 11, 2002-11 ,pp. : 1589-1598

Informa Healthcare

Access to resources Recommend Favorite

The modern treatment of ventricular arrhythmias: drugs or defibrillators

By Gill J S  

Clinical Medicine, Vol. 33, Iss. 2, 1999-03 ,pp. : 116-119

Royal College Of Physicians

Access to resources Recommend Favorite

Flecainide: Bradycardia and atrial fibrillation: case report

By  

Reactions Weekly, Vol. 1, Iss. 1286, 2010-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite